Citations

Clear

9383 citation(s) found for "Thomas, PS".

NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Jiang, Zhifan , Parida, Abhijeet , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , El-Diari, Mays, Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Brodsky, Michael A., Donahue, Sean P., Oattes, Julius, Reddy, Alyssa , Linguraru, Marius George , Fisher, Michael J. , Avery, Robert A. , Gutmann, David H. , Blank, Peter M K de , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Borchert, Mark , Bouffet, Éric , Wolf, David S. , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.582 Get It

Abstract BACKGROUND NF1-OPGs are amorphous tumors involving either single or multiple locations (optic nerve, chiasm, tract) along the anterior visual pathway (AVP). In this prospective study, we investigated how volumetric MRI measures of the AVP as well as other clinical variables are associated with treatment decisions in children with newly diagnosed NF1-OPGs. METHODS Children with newly diagnosed NF1-OPG whose MRI included a T1-weighted volumetric sequence without significant artifact at their enrollment visit were eligible for inclusion. All subjects underwent a quantitative ophthalmic exam to determine if visual acuity (VA) was normal. The neuro-oncologist/NF1 expert determined whether the subject would be observed or undergo treatment at that baseline visit. Volumetric MRI analysis was automatically performed using a deep learning network that measured AVP volume (mm3). Non-parametric group comparisons and multivariable logistic regression models evaluated the impact of age at enrollment, sex, NF1 inheritance type, AVP volume, and VA on the decision for immediate treatment with chemotherapy versus observation. RESULTS One-hundred twenty-three subjects met inclusion criteria. Subjects assigned to observation (N=112, 44% female) and subjects immediately treated with chemotherapy (N=11, 80% female) at enrollment were of similar age (2.7 and 2.8 years, respectively) and inheritance (p > 0.05). Abnormal VA was present more often in the treatment group (46%) compared to the observation group (17%, p <0.001). AVP volume was significantly greater in the treatment group (4,181.1mm3) compared to the observation group (1,819.8mm3, p <0.001). AVP volume, sex, and VA reached significance in univariable regression, however, in the multivariable regression model only the AVP volume (p < 0.001) was significantly associated with treatment initiation. DISCUSSION Children with greater NF1-OPG AVP volumes are treated more often compared with those with lower volumes. Volumetric measures of NF1-OPGs are a valuable metric in understanding treatment patterns and are positioned to help inform clinical decision making.
Banff 2022 Kidney Commentary: Reflections and Future Directions
Böhmig, Georg A. , Van-Groningen, Marian Clahsen, Cornell, Lynn D. , Vries, Aiko P. J. de , Huang, Edmund , Kozakowski, Nicolas , Perkowska‐Ptasińska, Agnieszka , Riella, Leonardo V. , Rosales, Ivy A. , Schinstock, Carrie, Simmonds, Naomi, Groningen, Marian C. Clahsen‐van , Riella, Leonardo V , Clahsen-van Groningen, Marian C , Cornell, Lynn , de Vries, Aiko P J , Rabant, Marion , Adam, Benjamin , Aubert, Olivier, Thaunat, Olivier , Willicombe, Michelle Kay

Mayo Clinic

Transplantation | June 18, 2024 | Volume: 109 | Issue: 2 | Pages: 292-299

10.1097/tp.0000000000005112 | PMID 38886879 Get It

In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely “microvascular inflammation/injury donor-specific antibodies–negative and C4d negative” and “probable antibody-mediated rejection,” into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell–mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell–mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
Guan, Yu, Puhalla, Shannon L. , Sahin, Ibrahim Halil, Deming, Dustin A. , Hong, Theodore S. , Rojas-Khalil, Yesenia, Dasari, Arvind , Kopetz, Scott , Lucas, Peter C. , Şahin, İbrahim Halil , Philip, Philip A. , Loree, Jonathan M. , Wolmark, Norman , Yothers, Greg , George, Thomas J. , Lieu, Christopher H.

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3641-TPS3641

10.1200/jco.2024.42.16_suppl.tps3641 Get It

TPS3641 Background: Currently, there are no biomarkers validated prospectively in randomized studies for resected colon cancer (CC) to determine need for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and may outperform traditional clinical and pathological features in prognosticating risk for recurrence. CC pts who do not have detectable ctDNA (ctDNA-) are at a much lower risk of recurrence and may be spared the toxicities associated with AC. Furthermore, for CC pts with detectable ctDNA (ctDNA+) who are at a very high risk of recurrence, the optimal AC regimen has not been established. We hypothesize that for pts whose CC has been resected, ctDNA status may be used to risk-stratify for making decisions about AC. Methods: In this prospective phase II/III trial, up to 1,912 pts with resected stage IIB, IIC, and III CC will be enrolled. Based on the post-operative ctDNA status using personalized and tumor-informed assay (Signatera, bespoke assay), those who are ctDNA- (Cohort A) will be randomized to immediate AC with fluoropyrimidine (FP)+oxaliplatin (Ox) for 3-6 mos per established guidelines vserial ctDNA monitoring. Patients who are ctDNA+ post-operatively, or with serial monitoring (Cohort B), will be randomized to FP+Ox v more intensive AC with addition of irinotecan (I) for 6 mos. One cycle of chemotherapy is allowed while awaiting ctDNA testing results for cohort assignment. The primary endpoints for Cohort A are time to ctDNA+ status (phase II) and disease-free survival (DFS) (phase III) in the immediate v delayed AC arms. The primary endpoint for Cohort B is DFS in the FP+Ox v FP+Ox+I arms for both phase II and phase III portions of the trial. Secondary endpoints include prevalence of detectable ctDNA post-operatively, time-to-event outcomes (overall survival and time to recurrence) by ctDNA status, and the assessment of compliance to adjuvant therapy. Biospecimens including archival tumor tissue, as well as post-operative plus serial matched/normal blood samples, will be collected for exploratory correlative research. Active enrollment across the NCTN started in June 2022 with CCTG sites joining in August 2023. Current accrual (as of 02-02-2024) is 240/1,912. NCT05174169. Support: U10-CA-180868, -180822; UG1CA-189867; Natera, Inc. Clinical trial information: NCT05174169 .
Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors.
Perez, Cesar A. , Hendrickson, Andrea E. Wahner , Orr, Douglas, Rojas‐Espaillat, Luis, Colón‐Otero, Gerardo , Reddick, Catherine W., Bayever, Eliel, Wee, Wen , Tolcher, Anthony W. , Murciano‐Goroff, Yonina R. , Anders, Carey K. , Hamilton, Erika , Swisher, Elizabeth M. , Mathews, Cara Amanda , Bashir, Babar , Adams, Gregory Paul

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3173-TPS3173

10.1200/jco.2024.42.16_suppl.tps3173 Get It

TPS3173 Background: ELU001, pasifolate exatecan, is an ultra-small nanoparticle drug conjugate, known as a CDC (~6 nm), designed to target and penetrate into solid tumors. Due to its size, ELU001 exhibits rapid renal elimination which is expected to reduce or eliminate the toxicities associated with many antibody drug conjugates. ELU001 has ~13 folic acid targeting moieties and ~21 cathepsin-B cleavable exatecan topoisomerase-1 inhibitor payloads covalently bound to short polyethylene glycol chains surrounding a silica core, the C’Dot. ELU001 binds to cancer cells expressing FRα and is internalized into the lysosome where it releases the exatecan payload. ELU001’s dose escalation study reported at ESMO Congress 2023 (1), examined weekly, bi-weekly (Q2W), and tri-weekly schedules over a range of doses in 42 patients. The study revealed that ELU001 could be administered safely and identified a dose level and schedule for the Expansion Studies described below. 22 of the patients with ovarian or endometrial cancers had >1 post-baseline scan(s), of these 2 had a PR and 19 had SD by RECIST v1.1 criteria. ELU001 demonstrated activity against tumors across a range of FRα expression levels, from low to high, retrospectively assessed using the VENTANA FOLR1 RxDx assay and the PS2+ scoring system. Methods: The current multicenter, Tumor Group Expansion open-label phase 1/2 clinical trial investigates ELU001 in patients with ovarian and endometrial cancers and is enrolling three cohorts; 1) ovarian cancer with high FRα expression, 2) ovarian cancer with moderate and low expression and 3) endometrial cancer with low to high expression with assessments based upon the PS2+ scoring system (high = ≥ 75%, moderate = ≥ 50% to < 75%, low = 25% to < 50%, negative = <25% of tumor cells with 2+ or 3+ staining intensity). An initial exploratory dose of 2.0 mg/m2 Q2W was employed in all three cohorts and a second dose of 1.7 mg/m2 Q2W will be studied in the ovarian cancer cohorts. Patients will ultimately be randomized to one of two or more doses to optimize dosing for registration. Primary endpoint: Objective Response Rate (ORR); secondary endpoints include DOR, PFS, TFST, PFS2, OS, adverse events, PK, and ADA assessments. Approximately 20 patients per tumor group will be recruited in the U.S. 1. Ann. Oncol. (2023) 34 (suppl_2): S458-S497. Clinical trial information: NCT05001282 .
Patterns of cognitive domain abnormalities enhance discrimination of dementia risk prediction: The ARIC study
Pike, James Russell , Sharrett, A. Richey, Windham, B. Gwen , Sullivan, Kevin , Albert, Marilyn , Yaşar, Sevil , Burgard, Sheila , Gross, Alden L. , Sullivan, Kevin J , Pike, James R , Knopman, David S. , Gottesman, Rebecca F. , Mosley, Thomas H. , Walker, Keenan A. , Li, David D.-U.

Mayo Clinic

Alzheimer's & Dementia | June 15, 2024 | Volume: 20 | Issue: 7 | Pages: 4559-4571

10.1002/alz.13876 | PMID 38877664 Get It

AbstractINTRODUCTIONThe contribution of neuropsychological assessments to risk assessment for incident dementia is underappreciated.METHODSWe analyzed neuropsychological testing results in dementia‐free participants in the Atherosclerosis Risk in Communities (ARIC) study. We examined associations of index domain–specific neuropsychological test performance with incident dementia using cumulative incidence curves and Cox proportional hazards models.RESULTSAmong 5296 initially dementia‐free participants (mean [standard deviation] age of 75.8 [5.1] years; 60.1% women, 22.2% Black) over a median follow‐up of 7.9 years, the covariate‐adjusted hazard ratio varied substantially depending on the pattern of domain‐specific performance and age, in an orderly manner from single domain language abnormalities (lowest risk) to single domain executive or memory abnormalities, to multidomain abnormalities including memory (highest risk).DISCUSSIONBy identifying normatively defined cognitive abnormalities by domains based on neuropsychological test performance, there is a conceptually orderly and age‐sensitive spectrum of risk for incident dementia that provides valuable information about the likelihood of progression.Highlights Domain‐specific cognitive profiles carry enhanced prognostic value compared to mild cognitive impairment. Single‐domain non‐amnestic cognitive abnormalities have the most favorable prognosis. Multidomain amnestic abnormalities have the greatest risk for incident dementia. Patterns of domain‐specific risks are similar by sex and race.
Sex differences in the prevalence of individual chronic conditions in a cardiac rehabilitation population
Miller, Stephanie , Chacin-Suarez, A, Olson, Thomas P. , Gomes, P F

Mayo Clinic

European Journal of Preventive Cardiology | June 14, 2024 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwae175.418 Get It

Abstract Background The United States Department of Health and Human Services has defined 21 chronic conditions lasting one year or greater and which require ongoing medical treatment. The presence of multiple chronic conditions (multimorbidity) is closely linked to greater physical disability, increased health care utilization, reduced quality of life, and higher mortality rates. In the general population, studies have shown the prevalence of multimorbidity to be greater in females compared to males. Recently, data has suggested that patients enrolled in cardiac rehabilitation (CR) have a significantly greater number of chronic conditions compared to the general population. Whether these same sex differences in the prevalence of individual chronic conditions are present in the CR population has not been examined. Purpose The purpose of this study is to determine whether differences exist in the prevalence of individual chronic conditions between male and female CR patients. We hypothesize that female CR patients will demonstrate greater prevalence of individual chronic conditions compared to men. Methods Using the local Epidemiology Project records-linkage system, we identified patients who attended (≥1) CR sessions from 1995-2019. The prevalence of 21 chronic conditions was extracted from the patients’ medical records at the time of enrollment in CR (Table 1). We conducted chi-squared analysis to identify differences in the prevalence of each individual chronic condition between the sexes. Statistical significance was defined by p≤0.05. Results Of the 13,056 CR patients identified (age: 65.7±12.8 yrs old), 4,107 (31.5%) were female. Male CR patients were significantly younger compared to female counterparts (64.8±12.1 yrs old vs. 67.6±13.6 yrs old; p≤0.001). Females demonstrated a greater number of total chronic conditions compared to males (median (IQR): 7.0 (5.0, 9.0) vs 6.0 (5.0, 8.0); p≤0.001). Females demonstrated a greater prevalence of the following 12 individual chronic conditions compared to males: HTN, CHF, ARR, STR, ART, CAN, CPD, HEP, OST, ANX, DEM, and DEP (p≤0.05, for all). There was a trend for greater prevalence of ARR in females compared to males (p=0.07). In contrast, males experienced a greater prevalence of the following four chronic conditions compared to females: CAD, LIP, AST, and SUB (p≤0.001, for all). There were no differences between sexes for CKD (p=0.87), SZO (p=0.70), or AUT (p=0.31). Conclusion Our data suggest the trend for greater prevalence of chronic conditions in females in the general population is consistent within the CR population. Specifically, 12 of 21 (57%) individual chronic conditions were significantly more prevalent in female CR patients whereas only 4 (19%) conditions were more prevalent in males. These data emphasize the need to better understand the relationship between sex and risk for individual chronic conditions, particularly in patients enrolled in CR.
Prevalence of non-cardiometabolic chronic conditions between sexes in patients enrolled in cardiac rehabilitation
Miller, Sophie , Chacin-Suarez, A, Olson, Thomas P. , Gomes, Paulo Rodrigues

Mayo Clinic

European Journal of Preventive Cardiology | June 14, 2024 | Volume: 31 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwae175.419 Get It

Abstract Background Patients enrolled in cardiac rehabilitation (CR) demonstrate a greater burden of co-occurring chronic conditions (CC) compared to the general population. Studies have shown that the prevalence of multimorbidity among noninstitutionalized, civilian US adults is higher among women compared to men. These CC are often grouped and categorized as Cardiometabolic, Somatic, and Mental Health based on the origin and organ system the condition affects. Importantly, sex differences between categorizations of CC in patients undergoing CR has not been examined. Purpose Because patients enrolled in CR are known to have multiple Cardiometabolic conditions, the aim of this study is to examine sex differences in the prevalence of non-cardiometabolic conditions in the CR population. Methods We extracted data on all 21 CC defined by the US Department of Health and Human Services using the local Epidemiology Project records-linkage system. Our study population included participants who attended (≥1) CR sessions from 1995 to 2019. The CC were categorized into cardiometabolic (CMC), Somatic, and Mental health groups (Table 1), and as CMC only, CMC + Somatic only, CMC + Mental health only, and CMC + Somatic + Mental health groups (Table 2). The sex differences in the number of CC within these groups were analyzed by Kruskal-Wallis test and prevalence were analyzed by Pearson’s Chi-squared test, where p&lt;0.05 was significant. Results We identified 13,056 CR patients (68.5% males) who were ≥18 years old with a mean age of 65.7±12.7 yrs (67.6±13.6 yrs in females and 64.8±12.1 yrs in males). Median [Q1, Q3] number of CC was 7 [5,9], with females having a greater number (7 [5, 9]) than males (6 [5,8]), p&lt;0.001. Both sexes had at least 1 CMC with a median of 5 [3,5] CMC and no differences between sexes (p&gt;0.05); however, females demonstrated more somatic and mental health conditions compared to males (p&lt;0.001, for both, Table 1). When grouping categories of CC, females demonstrated a higher number of CC in CMC + Somatic + Mental health as well as CMC + Somatic only groups (p&lt;0.001, for both, Table 2), with a higher prevalence in the former group only. While the number of CC in CMC + Mental health group was similar between sexes, the prevalence was lower in females. In contrast, the CMC only grouping demonstrated a higher number of CC and prevalence among males (p&lt;0.05). Conclusion Our data suggest that females enrolled in CR demonstrate a significantly higher number of CC compared to males. Although males have a higher prevalence of CMC, the prevalence of Somatic ± Mental health conditions in addition to CMC is significantly greater in females. These data demonstrate the importance of considering sex differences in the prevalence of non-CMC when formulating individualized treatment plans for CR patients.
ALK‐rearranged, CD34‐positive spindle cell neoplasms resembling dermatofibrosarcoma protuberans: a study of seven cases
Agrawal, Shruti , Ameline, Baptiste , Folpe, Andrew L. , Azzato, Elizabeth M. , Astbury, Caroline , Mentzel, Thomas , Knapp, Calvin , Rütten, Arno , Creytens, David, Sukov, William R. , Billings, Steven D. , Fritchie, Karen J. , Billings, Steven D , Creytens, David , Baumhoer, Daniel , Fritchie, Karen

Mayo Clinic

Histopathology | June 13, 2024 | Volume: 85 | Issue: 4 | Pages: 649-659

10.1111/his.15239 | PMID 38867577 Get It

AimsThe majority of dermatofibrosarcoma protuberans (DFSP) harbour PDGFB or PDGFD rearrangements. We encountered ALK expression/rearrangement in a PDGFB/D‐negative CD34‐positive spindle cell neoplasm with features similar to DFSP, prompting evaluation of ALK‐rearrangements in DFSP and plaque‐like CD34‐positive dermal fibroma (P‐LDF).Methods and ResultsWe searched the archives of academic institutions for cases previously coded as DFSP and P‐LDF. NGS‐naïve or PDGFB‐negative DFSP were screened for ALK (clone D5F3) expression by immunohistochemistry. NGS or ALK FISH was performed on ALK‐positive cases. Methylome profiling studies were performed and compared with conventional DFSP. One case of “DFSP” and two “P‐LDF” with ALK expression were identified from the archives, while four cases were detected prospectively. These seven cases (6F:1M; 8 months to 76 years) arose in the dermis of the arm (two), scalp, eyelid, thigh, abdomen, and shoulder and ranged from 0.4 to 4.2 cm. Tumours were composed of spindled cells and displayed a storiform growth pattern. Cytologic atypia was absent, and mitotic figures were scarce (0–2/10 HPFs, high power fields). The lesional cells were diffusely positive for CD34 and ALK and negative for S100 protein. By NGS (n = 5), ALK fusion partners included DCTN1 (2), PLEKHH2, and CLIP2 in DFSP‐like cases and FLNA in P‐LDF‐like lesions. ALK FISH was positive in one (of two) cases previously labelled P‐LDF. Methylome profiling of two (of three) ALK‐rearranged DFSP‐like tumours showed clustering with conventional DFSP in the UMAP dimension reduction plot. To date, no tumour has recurred (n = 2; 26, 27 months).ConclusionWe describe a cohort of novel ALK‐rearranged tumours with morphologic features similar to DFSP.
A world-wide study on delirium assessments and presence of protocols
Nydahl, Peter , Liu, Keibun , Bellelli, Giuseppe , Calle, Gabi Heras-La, Hoffmann, Magdalena , Jeitziner, Marie‐Madlen , Krewulak, Karla D. , Paulino, Maria Carolina , Haken, Rebecca von , Group, the WDAD Study, Abdalgany, Ahmed Gaber Ahmed, Aburaas, Amjad, Albakosh, Bashir Abobaker, Alhamdan, Hamza Ismail Ahmad, Aljbali, Akram Waled Rajab M, Al-Kandari, Fareeda, Anders, Daniel, Anderson, Marsali, Ashkenazy, Shelly , Avelino, Thiago, Bail, Kasia , Bakri, Ashraf , Baroum, Alaa Mohamed Ali , Brendt-Müller, Jennifer, Brobeil, Angelika, Byrnes, Tru , Cahill, Maria, Canelas, Maria Ana , Carroll, Ida, Conley, Amy, Cotton, Shannon A. , Couser, Mandy, Salgado, A., Cusworth, Elizabeth, Cvoro, Vera , Deosaran, Jordanna, Diebels, Merel, Docherty, Elaine A, Dossow, Vera von , Drennan, Megan, Egdeer, Akram Amin, Eichelsheim, Patrick, Elagili, Aissha Ali Saleh, Elsahl, Saifaleslam Jamal, Elshaikh, Hajer Alsadeg Mohammed, Fathi, Azza , Feige, Melanie, Fiest, Kirsten M. , Fong, Marleta Irene Joy, Fuchita, Mikita , Gaffney, Carol, Vich, Carola Giménez-Esparza, Feldmann, Nicole , Fitzpatrick, Neasa , Fong, Marleta Irene Joy, Goldberg, María Adela , Golüke, Nienke M.S. , Graaf, Marinette van der , Groenewald, Engelina , Gross, Renate , Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai Ahmad Hasan, Hamida, Bahaeddin Ben, Hamza, Monalyce, Hopkins, Jane , Hopkins, John , Jeyaseelan, Arveen , Kadhim, Ali Jawad, Kohler, S., Kooken, Rens , Khutwah, Ayman Salim Abu, Lange, Puck, Liefrink, Sharon, Lin, Yu‐Min , Loo, Shi Pei , Rodrigues, Sara Beatriz Lopes, MacDonald, Allan S., Madders, G, Massaro, Claudia, Maya, Kerri, Manioudaki, Sofia, Stewart, McKenna, Coimbra, Isabel , Miranda, Teresa, Mohamed, Mohamed A. , Mohammed, Mushin Mohammed Elhadi Agbna, Naeem, Fariha , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Noonan, Claire, Lopes, Maria Inês, Otmani, Zina , O’Reilly, Susan, Ozorio, Valerie, Palakashappa, Jessica, Pandya, Tej , Papadea, Panagiota, Papanikolaou, Metaxia, Pinardi, Elena , Pereira, Inês Filipa Pinto, Premathilaka, Chirantha , Pop‐Purceleanu, Monica , Puchegger, Marlene, Qalhoud, Nouralddeen Mohammed, Raasing, Maike, Ragheb, Dalia Talaat, Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Schimböck, Florian , Schmädig, Roman , Schoon, Yvonne , Sethia, Deepak , Sextl, Edith, Shah, Bhagyesh , Shaout, Dua’a, Sharabi, Alaa Fouad, Shields, Lynn, Smith, Kendall A. , Dam, Linda Smulders-van, Soiza, Roy L. , Spiegler, Andrea, Stocks, Lucy, Sumerauer, Stefan, Tam, Stephanie , Tan, Aik Haw, Tohsche, Peter, Torres, Raquel Gouveia, Toth, Chantal, Tousgaard, Iben, Vogt, Birgit, Walsh, Erica M., Ward‐Stockham, Kristel , Mart, Melinda Webb‐St, Wijnen-Meijer, Mariajne Elisabeth, Zastrow, Inke , Nydahl, Peter , Jeitziner, Marie-Madlen , Krewulak, Karla D , Benbenishty, Julie Sarah , Boogaard, Mark van den , Caplan, Gideon A. , Chung, Chi Ryang , Elhadi, Muhammed , Gurjar, Mohan , Mailhot, Tanya , Morandi, Alessandro , Nawa, Ricardo Kenji , Oh, Esther S , Collet, Marie Oxenbøll , Lindroth, Heidi , Group, the WDAD Study, Abdelmohsen, Sarah Magdy , Aggar, Christina , Alkandari, Farah, Alkaseek, Akram Mohammed , Anders, Daniel, Anderson, Marsali, Blackwood, Bronagh , Brendt-Müller, Jennifer , Burke, Richard, Cacciatore, Stefano , Cahill, Maria, Conley, Amy, Costello, Maria , Diebels, Merel, Elshaikh, Hajer Alsadeg Mohammed, Emme, Christina , Exl, Matthias Thomas , Fong, Marleta Irene Joy, Gaffney, Carol, Fitzgerald, Rachel, Fong, Marleta Irene Joy, Graaf, Mirjam, Segers, Camilla Grube, Hadi, Renate, Hamdan, Qusai, Hetland, Breanna , Hopkins, Jane Adele, Ibrahim, Said A. , Imbrìaco, Guglielmo , Inoue, Shigeaki , Kadhim, Ali Jawad, Kohler, Sabrina, Korompeli, Anna , Krüger, Lars , Lange, Puck, Rodrigues, Sara Beatriz Lopes, MacDonald, Allan, McAndrew, Natalie S. , Mohamed, Mohamed Anwar Abdelsalam, Mohammed, Mushin Mohammed Elhadi Agbna, Mulkey, Malissa , Nakamura, Kensuke , Nam, Mi-Ryeo, Newman, Elaine, Nicol, Renae, Olotu, Cynthia , Ornago, Alice Margherita , O’Reilly, Susan, Penfold, Rose , Pereira, Inês Filipa Pinto, Quinn, Terence J , Raasing, Maike Wm, Rajhans, Prasad Anant , Ramadan, Nuri, Rubel, Mushabbir Hossain, Sainsbury, Kate, Salis, Francesco , Sharabi, Alaa Fouad, Smith, Kendall, Tam, Stephanie, Timmons, Suzanne , Torres, Raquel Gouveia, Tsolaki, Vasiliki , Castro, Roberta Esteves Vieira de , Vogt, Birgit, Walsh, Erica, Wefer, Franziska , Wøien, Hilde , Zazzara, Maria Beatrice

Mayo Clinic

Age and Ageing | June 12, 2024 | Volume: 53 | Issue: 7 | Pages: No page available

10.1093/ageing/afae129 | PMID 38952186 Get It

Abstract Background Delirium is a common complication of older people in hospitals, rehabilitation and long-term facilities. Objective To assess the worldwide use of validated delirium assessment tools and the presence of delirium management protocols. Design Secondary analysis of a worldwide one-day point prevalence study on World Delirium Awareness Day, 15 March 2023. Setting Cross-sectional online survey including hospitals, rehabilitation and long-term facilities. Methods Participating clinicians reported data on delirium, the presence of protocols, delirium assessments, delirium-awareness interventions, non-pharmacological and pharmacological interventions, and ward/unit-specific barriers. Results Data from 44 countries, 1664 wards/units and 36 048 patients were analysed. Validated delirium assessments were used in 66.7% (n = 1110) of wards/units, 18.6% (n = 310) used personal judgement or no assessment, and 10% (n = 166) used other assessment methods. A delirium management protocol was reported in 66.8% (n = 1094) of wards/units. The presence of protocols for delirium management varied across continents, ranging from 21.6% (on 21/97 wards/units) in Africa to 90.4% (235/260) in Australia, similar to the use of validated delirium assessments with 29.6% (29/98) in Africa to 93.5% (116/124) in North America. Wards/units with a delirium management protocol [n = 1094/1664, 66.8%] were more likely to use a validated delirium test than those without a protocol [odds ratio 6.97 (95% confidence interval 5.289–9.185)]. The presence of a delirium protocol increased the chances for valid delirium assessment and, likely, evidence-based interventions. Conclusion Wards/units that reported the presence of delirium management protocols had a higher probability of using validated delirium assessments tools to assess for delirium.
Bidirectional needs assessment of otolaryngology–head and neck surgery short‐term surgical trips in Zimbabwe
Green, Katerina J. , Matinhira, Naboth, Jain, Amiti , Arya, Priya , Douse, Dontre’ M. , Dzongodza, Titus , Chidziva, Clemence, Wiedermann, Joshua P. , Green, Katerina , Arya, Priya

Mayo Clinic

Laryngoscope Investigative Otolaryngology | June 12, 2024 | Volume: 9 | Issue: 3 | Pages: No page available

10.1002/lio2.1278 | PMID 38867854 Get It

AbstractObjectivesTo describe findings from an otolaryngology‐specific needs assessment tool in Zimbabwe.MethodsSurveys were developed and shared with Low‐Middle Income Country (LMIC) hosting institutions in Zimbabwe and to High‐Income Country surgical trip participants (HIC). Respondents were otolaryngologists identified online and through professional networks who had participated in a surgical trip.ResultsThe most common procedures Zimbabwe otolaryngologists reported treating were adenotonsillectomy (85.7%), chronic rhinosinusitis (71.4%), chronic otitis (57.1%), and head and neck tumor intervention (57.1%). The most common untreatable conditions that host physicians wanted to treat were skull base surgery (71.4%), flap reconstructions (57.1%), and laryngotracheal reconstruction (57.1%). The largest discrepancy between host desires and visiting team offerings were flap reconstruction (57.1%), nasal bone deformities (37.1%), and laryngotracheal reconstruction (17.1%). Perceptions of short‐term surgical trips (STST) were recorded for host and visiting teams, and important differences between the public and private sectors of care in Zimbabwe were also identified.ConclusionThe surveys utilized in this study served as a bidirectional needs assessment of the requirements and care goals of host institutions and visiting teams in Zimbabwe. Differences between public and private sectors of care, particularly regarding infrastructure, resources, and surgical goals, were revealed, and the results can be utilized as part of efforts to maximize efforts within global surgical partnerships.Level of EvidenceVI.